In the last year, Dexcom Inc., of San Diego, has seen its market cap grow exponentially – from less than $5 billion in February 2018 to roughly $12.5 billion now. That followed about three years of stagnant valuation for the continuous glucose monitor (CGM) player. The strength of the recent Dexcom run-up has been on the thesis of widespread U.S. market penetration, particularly as it became the first CGM player to gain Medicare reimbursement.

Interoperability took center stage at the recent Healthcare Information and Management Systems Society (HIMSS) Conference in Orlando, Fla., with major news coming from the Centers for Medicare and Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC), as well as the release of a report from a group of experts.